Bostwick Laboratories Receives Majority Investment from Metalmark Capital
Summary
Bostwick Laboratories, Inc., a provider of urologic anatomic pathology laboratory services in the United States, has received a majority investment of undisclosed amount from New York-based private equity firm Metalmark Capital. Following the investment, Founder and CEO, Dr. David G. Bostwick, will continue to be a major shareholder in the company. Bostwick Laboratories intends to use the proceeds from the investment to pursue growth initiatives and expand development of its pathology laboratory services, which specialize in the monitoring and diagnosis of cancer. Founded in 1999, the company is a large full-service, anatomic pathology lab, which services over 8,000 physicians across the U.S. Bostwick has a leading market share within the urologic pathology lab testing industry and also provides testing services within other anatomic pathology sub-specialties, including gynecology, dermatology, gastroenterology, nephrology and hematology. The company maintains lab operations in Glen Allen, VA, Uniondale, NY, El Paso, TX and Orlando, FL.